{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:03Z","timestamp":1783498443818,"version":"3.55.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["Project 101169266"],"award-info":[{"award-number":["Project 101169266"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["HORIZON-MSCA-2023-DN-01"],"award-info":[{"award-number":["HORIZON-MSCA-2023-DN-01"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myotonic dystrophies (DM) are autosomal dominant, multisystemic disorders characterized by myotonia and progressive muscle weakness. Extramuscular multisystem symptoms include involvement of the respiratory, cardiac and central nervous systems, and endocrine and autoimmune alterations. While there is significant overlap in key symptoms due to a shared molecular backbone of alternative splicing, DM1 and DM2 differ in genetic origin, disease progression, and aspects of molecular pathology. Currently, DM management focuses on symptoms, and the wide clinical variation leads to long diagnostic delay. This highlights the need for reliable biomarkers to aid diagnosis, prognosis, and monitoring. As the understanding of molecular mechanisms in DM improves, new therapies are rapidly emerging, further emphasizing the need for reliable biomarkers to assess short- and long-term treatment efficacy. This review covers current biomarker research, including imaging-based, muscle-derived, and soluble liquid biopsy approaches. While established DM biomarkers are limited, with research disproportionately focused on DM1, multiple markers of alternative splicing pathology show promise. However, their reliance on invasive sampling restricts cohort size and longitudinal assessment. Consequently, efforts are shifting toward developing minimally invasive biomarkers. While some soluble markers, like muscle-specific circulating microRNAs, correlate with clinical measures, inconsistent detection, and limited evaluation of disease specificity point to the need for further research in larger, more diverse longitudinal cohorts. Future progress will depend on validating existing candidates, discovering new biomarkers addressing these limitations, and reducing the imbalance between DM1- and DM2-focused research to advance DM diagnosis, management, and therapy development.<\/jats:p>","DOI":"10.1007\/s00415-026-13888-w","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T09:28:36Z","timestamp":1781429316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current biomarker development in myotonic dystrophies"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6820-0583","authenticated-orcid":false,"given":"Malin","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-6031","authenticated-orcid":false,"given":"Daniel H.","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-7313","authenticated-orcid":false,"given":"Felix","family":"Kleefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3359-3837","authenticated-orcid":false,"given":"Peter","family":"Meinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-8131","authenticated-orcid":false,"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"13888_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68:799\u2013808. https:\/\/doi.org\/10.1016\/0092-8674(92)90154-5","journal-title":"Cell"},{"key":"13888_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","volume":"255","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2019 untranslated region of the gene. Science 255:1253\u20131255. https:\/\/doi.org\/10.1126\/science.1546325","journal-title":"Science"},{"key":"13888_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1062125","volume":"293","author":"CL Liquori","year":"2001","unstructured":"Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL et al (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293:864\u2013867. https:\/\/doi.org\/10.1126\/science.1062125","journal-title":"Science"},{"key":"13888_CR4","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/hmg\/ddl103","volume":"15","author":"JM Margolis","year":"2006","unstructured":"Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LPW (2006) DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 15:1808\u20131815. https:\/\/doi.org\/10.1093\/hmg\/ddl103","journal-title":"Hum Mol Genet"},{"key":"13888_CR5","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","volume":"96","author":"NE Johnson","year":"2021","unstructured":"Johnson NE, Butterfield RJ, Mayne K, Newcomb T, Imburgia C, Dunn D et al (2021) Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program. Neurology 96:e1045\u2013e1053. https:\/\/doi.org\/10.1212\/WNL.0000000000011425","journal-title":"Neurology"},{"key":"13888_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241290353","author":"S Peric","year":"2024","unstructured":"Peric S, Ivanovic V, Ashley E-J, Esparis B, Campbell C, Wenninger S et al (2024) International collaboration to improve knowledge on myotonic dystrophy type 2. J Neuromuscul Dis. https:\/\/doi.org\/10.1177\/22143602241290353","journal-title":"J Neuromuscul Dis"},{"key":"13888_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000524734","volume":"56","author":"Q Liao","year":"2022","unstructured":"Liao Q, Zhang Y, He J, Huang K (2022) Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis. Neuroepidemiology 56:163\u2013173. https:\/\/doi.org\/10.1159\/000524734","journal-title":"Neuroepidemiology"},{"key":"13888_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ejhg.2011.23","volume":"19","author":"T Suominen","year":"2011","unstructured":"Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C et al (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19:776\u2013782. https:\/\/doi.org\/10.1038\/ejhg.2011.23","journal-title":"Eur J Hum Genet"},{"key":"13888_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10072-016-2805-5","volume":"38","author":"G Meola","year":"2017","unstructured":"Meola G, Cardani R (2017) Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci 38:535\u2013546. https:\/\/doi.org\/10.1007\/s10072-016-2805-5","journal-title":"Neurol Sci"},{"key":"13888_CR10","unstructured":"Kleefeld F, Erdmann H, Schoser B (2006) Myotonic dystrophy type 2. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al (eds). University of Washington, Seattle. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1466\/"},{"key":"13888_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gde.2017.01.007","volume":"44","author":"K Yum","year":"2017","unstructured":"Yum K, Wang ET, Kalsotra A (2017) Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes. Curr Opin Genet Dev 44:30\u201337. https:\/\/doi.org\/10.1016\/j.gde.2017.01.007","journal-title":"Curr Opin Genet Dev"},{"key":"13888_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","volume":"32","author":"CA Thornton","year":"2014","unstructured":"Thornton CA (2014) Myotonic dystrophy. Neurol Clin 32:705\u2013719. https:\/\/doi.org\/10.1016\/j.ncl.2014.04.011","journal-title":"Neurol Clin"},{"key":"13888_CR13","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1212\/wnl.0000000000008056","volume":"93","author":"SA Cumming","year":"2019","unstructured":"Cumming SA, Jimenez-Moreno C, Okkersen K, Wenninger S, Daidj F, Hogarth F et al (2019) Genetic determinants of disease severity in the Myotonic dystrophy type 1 optimistic cohort. Neurology 93:e995-1009. https:\/\/doi.org\/10.1212\/wnl.0000000000008056","journal-title":"Neurology"},{"key":"13888_CR14","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/hmg\/ddz055","volume":"28","author":"G Overend","year":"2019","unstructured":"Overend G, L\u00e9gar\u00e9 C, Mathieu J, Bouchard L, Gagnon C, Monckton DG (2019) Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. Hum Mol Genet 28:2245\u20132254. https:\/\/doi.org\/10.1093\/hmg\/ddz055","journal-title":"Hum Mol Genet"},{"key":"13888_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/hmg\/ddaa123","volume":"29","author":"F Morales","year":"2020","unstructured":"Morales F, V\u00e1squez M, Corrales E, Vindas-Smith R, Santamar\u00eda-Ulloa C, Zhang B et al (2020) Longitudinal increases in somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 are associated with variation in age-at-onset. Hum Mol Genet 29:2496\u20132507. https:\/\/doi.org\/10.1093\/hmg\/ddaa123","journal-title":"Hum Mol Genet"},{"key":"13888_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fneur.2018.00303","volume":"9","author":"S Wenninger","year":"2018","unstructured":"Wenninger S, Montagnese F, Schoser B (2018) Core clinical phenotypes in myotonic dystrophies. Front Neurol 9:303. https:\/\/doi.org\/10.3389\/fneur.2018.00303","journal-title":"Front Neurol"},{"key":"13888_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-55678-7_3","author":"M Nakamori","year":"2016","unstructured":"Nakamori M, Takahashi MP (2016) Myotonic dystrophy. Transl Res Muscular Dystrophy. https:\/\/doi.org\/10.1007\/978-4-431-55678-7_3","journal-title":"Transl Res Muscular Dystrophy"},{"key":"13888_CR18","first-page":"252","volume":"37","author":"M Vujnic","year":"2018","unstructured":"Vujnic M, Peric S, Calic Z, Benovic N, Nisic T, Pesovic J et al (2018) Metabolic impairments in patients with myotonic dystrophy type 2. Acta Myol 37:252","journal-title":"Acta Myol"},{"key":"13888_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1212\/01.wnl.0000054481.84978.f9","volume":"60","author":"JW Day","year":"2003","unstructured":"Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W et al (2003) Myotonic dystrophy type 2. Neurology 60:657\u2013664. https:\/\/doi.org\/10.1212\/01.wnl.0000054481.84978.f9","journal-title":"Neurology"},{"key":"13888_CR20","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1212\/01.wnl.0000065898.61358.09","volume":"60","author":"A Vihola","year":"2003","unstructured":"Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A et al (2003) Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM\/DM2. Neurology 60:1854\u20131857. https:\/\/doi.org\/10.1212\/01.wnl.0000065898.61358.09","journal-title":"Neurology"},{"key":"13888_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fneur.2018.00646","volume":"9","author":"M Minnerop","year":"2018","unstructured":"Minnerop M, Gliem C, Kornblum C (2018) Current progress in CNS imaging of myotonic dystrophy. Front Neurol 9:646. https:\/\/doi.org\/10.3389\/fneur.2018.00646","journal-title":"Front Neurol"},{"key":"13888_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00415-010-5498-3","volume":"257","author":"VM Romeo","year":"2010","unstructured":"Romeo VM, Muntoni F, Ferrati C, Squarzanti F, Sorar\u00f9 G, Palmieri A et al (2010) Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol 257:1246\u20131255. https:\/\/doi.org\/10.1007\/s00415-010-5498-3","journal-title":"J Neurol"},{"key":"13888_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/cpj.0000000000000645","volume":"9","author":"B Schoser","year":"2019","unstructured":"Schoser B, Montagnese F, Bassez G, Fossati B, Gamez J, Heatwole C et al (2019) Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract 9:343\u2013353. https:\/\/doi.org\/10.1212\/cpj.0000000000000645","journal-title":"Neurol Clin Pract"},{"key":"13888_CR24","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1007\/s00415-017-8653-2","volume":"264","author":"F Montagnese","year":"2017","unstructured":"Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B (2017) Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol 264:2472\u20132480. https:\/\/doi.org\/10.1007\/s00415-017-8653-2","journal-title":"J Neurol"},{"key":"13888_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jns.2019.02.012","volume":"399","author":"S Rossi","year":"2019","unstructured":"Rossi S, Della Marca G, Ricci M, Perna A, Nicoletti T, Brunetti V et al (2019) Prevalence and predictor factors of respiratory impairment in a large cohort of patients with myotonic dystrophy type 1 (DM1): a retrospective, cross sectional study. J Neurol Sci 399:118\u2013124. https:\/\/doi.org\/10.1016\/j.jns.2019.02.012","journal-title":"J Neurol Sci"},{"key":"13888_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111874","volume":"22","author":"MS Mahadevan","year":"2021","unstructured":"Mahadevan MS, Yadava RS, Mandal M (2021) Cardiac pathology in myotonic dystrophy type 1. Int J Mol Sci 22:11874. https:\/\/doi.org\/10.3390\/ijms222111874","journal-title":"Int J Mol Sci"},{"key":"13888_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.smrv.2012.01.001","volume":"16","author":"YA Dauvilliers","year":"2012","unstructured":"Dauvilliers YA, Laberge L (2012) Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep Med Rev 16:539\u2013545. https:\/\/doi.org\/10.1016\/j.smrv.2012.01.001","journal-title":"Sleep Med Rev"},{"key":"13888_CR28","doi-asserted-by":"publisher","first-page":"1369332","DOI":"10.3389\/fncel.2024.1369332","volume":"18","author":"Y Wu","year":"2024","unstructured":"Wu Y, Wei Q, Lin J, Shang H, Ou R (2024) Cognitive impairment, neuroimaging abnormalities, and their correlations in myotonic dystrophy: a comprehensive review. Front Cell Neurosci Front Media 18:1369332. https:\/\/doi.org\/10.3389\/fncel.2024.1369332","journal-title":"Front Cell Neurosci Front Media"},{"key":"13888_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1212\/wnl.0000000000004420","volume":"89","author":"JE Hilbert","year":"2017","unstructured":"Hilbert JE, Barohn RJ, Clemens PR, Luebbe E, Martens WL, McDermott MW et al (2017) High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. Neurology 89:1348\u20131354. https:\/\/doi.org\/10.1212\/wnl.0000000000004420","journal-title":"Neurology"},{"key":"13888_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1212\/wnl.0b013e318260cbe6","volume":"79","author":"C Heatwole","year":"2012","unstructured":"Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP et al (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79:348\u2013357. https:\/\/doi.org\/10.1212\/wnl.0b013e318260cbe6","journal-title":"Neurology"},{"key":"13888_CR31","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41433-018-0161-9","volume":"32","author":"D Pagoulatos","year":"2018","unstructured":"Pagoulatos D, Kapsala Z, Makri OE, Georgakopoulos CD (2018) Christmas tree cataract and myotonic dystrophy type 1. Eye 32:1794\u20131795. https:\/\/doi.org\/10.1038\/s41433-018-0161-9","journal-title":"Eye"},{"key":"13888_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ene.12542","volume":"22","author":"JR Dahlqvist","year":"2015","unstructured":"Dahlqvist JR, \u00d8rngreen MC, Witting N, Vissing J (2015) Endocrine function over time in patients with myotonic dystrophy type 1. Eur J Neurol 22:116\u2013122. https:\/\/doi.org\/10.1111\/ene.12542","journal-title":"Eur J Neurol"},{"key":"13888_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-025-01358-6","author":"J Nemoto","year":"2025","unstructured":"Nemoto J, Nakamori M (2025) Molecular genetics of myotonic dystrophy and the evolution of therapeutic approaches. J Hum Genet. https:\/\/doi.org\/10.1038\/s10038-025-01358-6","journal-title":"J Hum Genet"},{"key":"13888_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41582-025-01139-x","volume":"21","author":"L Rahm","year":"2025","unstructured":"Rahm L, Hale MA, Raaijmakers RHL, Marrero Qui\u00f1ones A, Patki T, Johnson NE et al (2025) Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives. Nat Rev Neurol 21:623\u2013641. https:\/\/doi.org\/10.1038\/s41582-025-01139-x","journal-title":"Nat Rev Neurol"},{"key":"13888_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/22143602251365101","author":"JA Berglund","year":"2025","unstructured":"Berglund JA, Novack A, Holder II, Ray S, Johnson NE (2025) Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy type 1 (DM1) clinical trials. J Neuromuscul Dis. https:\/\/doi.org\/10.1177\/22143602251365101","journal-title":"J Neuromuscul Dis"},{"key":"13888_CR36","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/sj.emboj.7600300","volume":"23","author":"TH Ho","year":"2004","unstructured":"Ho TH, Charlet-B N, Poulos MG, Singh G, Swanson MS, Cooper TA (2004) Muscleblind proteins regulate alternative splicing. EMBO J 23:3103\u20133112. https:\/\/doi.org\/10.1038\/sj.emboj.7600300","journal-title":"EMBO J"},{"key":"13888_CR37","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","volume":"15","author":"X Lin","year":"2006","unstructured":"Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT et al (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15:2087\u20132097. https:\/\/doi.org\/10.1093\/hmg\/ddl132","journal-title":"Hum Mol Genet"},{"key":"13888_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1083\/jcb.128.6.995","volume":"128","author":"KL Taneja","year":"1995","unstructured":"Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH (1995) Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 128:995\u20131002. https:\/\/doi.org\/10.1083\/jcb.128.6.995","journal-title":"J Cell Biol"},{"issue":"1","key":"13888_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/ijms21010094","volume":"21","author":"L Timchenko","year":"2020","unstructured":"Timchenko L (2020) Correction of RNA-binding protein CUGBP1 and GSK3\u03b2 signaling as therapeutic approach for congenital and adult myotonic dystrophy type 1. Int J Mol Sci 21(1):94. https:\/\/doi.org\/10.3390\/ijms21010094","journal-title":"Int J Mol Sci"},{"key":"13888_CR40","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/hmg\/ddr299","volume":"20","author":"M Wojciechowska","year":"2011","unstructured":"Wojciechowska M, Krzyzosiak WJ (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 20:3811\u20133821. https:\/\/doi.org\/10.1093\/hmg\/ddr299","journal-title":"Hum Mol Genet"},{"key":"13888_CR41","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/bst0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee JE, Cooper TA (2009) Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 37:1281\u20131286. https:\/\/doi.org\/10.1042\/bst0371281","journal-title":"Biochem Soc Trans"},{"key":"13888_CR42","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1172\/JCI32308","volume":"117","author":"G-S Wang","year":"2007","unstructured":"Wang G-S, Kearney DL, Biasi MD, Taffet G, Cooper TA (2007) Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 117:2802\u20132811. https:\/\/doi.org\/10.1172\/JCI32308","journal-title":"J Clin Invest"},{"key":"13888_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","volume":"28","author":"NM Kuyumcu-Martinez","year":"2007","unstructured":"Kuyumcu-Martinez NM, Wang G-S, Cooper TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28:68\u201378. https:\/\/doi.org\/10.1016\/j.molcel.2007.07.027","journal-title":"Mol Cell"},{"key":"13888_CR44","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1093\/nar\/gkp1209","volume":"38","author":"ES Goers","year":"2010","unstructured":"Goers ES, Purcell J, Voelker RB, Gates DP, Berglund JA (2010) MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res 38:2467\u20132484. https:\/\/doi.org\/10.1093\/nar\/gkp1209","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"13888_CR45","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41467-018-04370-x","volume":"9","author":"C Sellier","year":"2018","unstructured":"Sellier C, Cerro-Herreros E, Blatter M, Freyermuth F, Gaucherot A, Ruffenach F et al (2018) rbFOX1\/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1\/type 2 differences. Nat Commun 9(1):2009. https:\/\/doi.org\/10.1038\/s41467-018-04370-x","journal-title":"Nat Commun"},{"key":"13888_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.nmd.2006.12.015","volume":"17","author":"TM Wheeler","year":"2007","unstructured":"Wheeler TM, Krym MC, Thornton CA (2007) Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1. Neuromuscul Disord 17:242\u2013247. https:\/\/doi.org\/10.1016\/j.nmd.2006.12.015","journal-title":"Neuromuscul Disord"},{"key":"13888_CR47","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1101\/gr.184390.114","volume":"25","author":"ET Wang","year":"2015","unstructured":"Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ et al (2015) Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res 25:858\u2013871. https:\/\/doi.org\/10.1101\/gr.184390.114","journal-title":"Genome Res"},{"key":"13888_CR48","doi-asserted-by":"publisher","first-page":"20333","DOI":"10.1073\/pnas.0809045105","volume":"105","author":"A Kalsotra","year":"2008","unstructured":"Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB et al (2008) A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 105:20333\u201320338. https:\/\/doi.org\/10.1073\/pnas.0809045105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13888_CR49","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/mcb.21.4.1285-1296.2001","volume":"21","author":"AN Ladd","year":"2001","unstructured":"Ladd AN, Charlet-B. N, Cooper TA (2001) The CELF family of RNA-binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell Biol 21:1285\u20131296. https:\/\/doi.org\/10.1128\/mcb.21.4.1285-1296.2001","journal-title":"Mol Cell Biol"},{"key":"13888_CR50","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1093\/hmg\/dds240","volume":"21","author":"BL Fogel","year":"2012","unstructured":"Fogel BL, Wexler E, Wahnich A, Friedrich T, Vijayendran C, Gao F et al (2012) RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. Hum Mol Genet 21:4171\u20134186. https:\/\/doi.org\/10.1093\/hmg\/dds240","journal-title":"Hum Mol Genet"},{"key":"13888_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jmb.2007.01.088","volume":"368","author":"W Chen","year":"2007","unstructured":"Chen W, Wang Y, Abe Y, Cheney L, Udd B, Li Y-P (2007) Haploinsuffciency for Znf9 in Znf9\u2212 Mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol 368:8\u201317. https:\/\/doi.org\/10.1016\/j.jmb.2007.01.088","journal-title":"J Mol Biol"},{"key":"13888_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00649-17","author":"C Wei","year":"2018","unstructured":"Wei C, Stock L, Schneider-Gold C, Sommer C, Timchenko NA, Timchenko L (2018) Reduction of cellular nucleic acid-binding protein encoded by a myotonic dystrophy type 2 gene causes muscle atrophy. Mol Cell Biol. https:\/\/doi.org\/10.1128\/mcb.00649-17","journal-title":"Mol Cell Biol"},{"key":"13888_CR53","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1073\/pnas.1716617115","volume":"115","author":"\u0141J Sznajder","year":"2018","unstructured":"Sznajder \u0141J, Thomas JD, Carrell EM, Reid T, McFarland KN, Cleary JD et al (2018) Intron retention induced by microsatellite expansions as a disease biomarker. Proc Natl Acad Sci U S A 115:4234\u20134239. https:\/\/doi.org\/10.1073\/pnas.1716617115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13888_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ng0796-325","volume":"13","author":"S Reddy","year":"1996","unstructured":"Reddy S, Smith DBJ, Rich MM, Leferovich JM, Reilly P, Davis BM et al (1996) Mice lacking the myotonic dystrophy protein kinase develop a late-onset progressive myopathy. Nat Genet 13:325\u2013335. https:\/\/doi.org\/10.1038\/ng0796-325","journal-title":"Nat Genet"},{"key":"13888_CR55","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","volume":"25","author":"ST Carrell","year":"2016","unstructured":"Carrell ST, Carrell EM, Auerbach D, Pandey SK, Bennett CF, Dirksen RT et al (2016) Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice. Hum Mol Genet 25:4328\u20134338. https:\/\/doi.org\/10.1093\/hmg\/ddw266","journal-title":"Hum Mol Genet"},{"key":"13888_CR56","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1086\/301711","volume":"62","author":"P Steinbach","year":"1998","unstructured":"Steinbach P, Gl\u00e4ser D, Vogel W, Wolf M, Schwemmle S (1998) The DMPK gene of severely affected myotonic dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat. Am J Hum Genet 62:278\u2013285. https:\/\/doi.org\/10.1086\/301711","journal-title":"Am J Hum Genet"},{"key":"13888_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddq427","volume":"20","author":"A L\u00f3pez Castel","year":"2011","unstructured":"L\u00f3pez Castel A, Nakamori M, Tom\u00e9 S, Chitayat D, Gourdon G, Thornton CA et al (2011) Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissue. Hum Mol Genet 20:1\u201315. https:\/\/doi.org\/10.1093\/hmg\/ddq427","journal-title":"Hum Mol Genet"},{"key":"13888_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/567435","volume":"2013","author":"JR Brouwer","year":"2013","unstructured":"Brouwer JR, Huguet A, Nicole A, Munnich A, Gourdon G (2013) Transcriptionally repressive chromatin remodelling and CpG methylation in the presence of expanded CTG-repeats at the DM1 locus. J Nucleic Acids 2013:1\u201316. https:\/\/doi.org\/10.1155\/2013\/567435","journal-title":"J Nucleic Acids"},{"key":"13888_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.stemcr.2015.06.003","volume":"5","author":"S Yanovsky-Dagan","year":"2015","unstructured":"Yanovsky-Dagan S, Avitzour M, Altarescu G, Renbaum P, Eldar-Geva T, Schonberger O et al (2015) Uncovering the role of hypermethylation by CTG expansion in myotonic dystrophy type 1 using mutant human embryonic stem cells. Stem Cell Reports 5:221\u2013231. https:\/\/doi.org\/10.1016\/j.stemcr.2015.06.003","journal-title":"Stem Cell Reports"},{"key":"13888_CR60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ajhg.2017.01.033","volume":"100","author":"L Barb\u00e9","year":"2017","unstructured":"Barb\u00e9 L, Lanni S, L\u00f3pez-Castel A, Franck S, Spits C, Keymolen K et al (2017) CpG methylation, a parent-of-origin effect for maternal-biased transmission of congenital myotonic dystrophy. Am J Hum Genet 100:488\u2013505. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.033","journal-title":"Am J Hum Genet"},{"key":"13888_CR61","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/biomedicines10061372","volume":"10","author":"E Koehorst","year":"2022","unstructured":"Koehorst E, Odria R, Cap\u00f3 J, N\u00fa\u00f1ez-Manch\u00f3n J, Arbex A, Almendrote M et al (2022) An integrative analysis of DNA methylation pattern in myotonic dystrophy type 1 samples reveals a distinct DNA methylation profile between tissues and a novel muscle-associated epigenetic dysregulation. Biomedicines 10:1372\u20131372. https:\/\/doi.org\/10.3390\/biomedicines10061372","journal-title":"Biomedicines"},{"key":"13888_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac154","author":"M Nakamori","year":"2022","unstructured":"Nakamori M, Shimizu H, Ogawa K, Hasuike Y, Nakajima T, Sakurai H et al (2022) Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcac154","journal-title":"Brain Commun"},{"key":"13888_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cell.2018.08.005","volume":"175","author":"JH Sun","year":"2018","unstructured":"Sun JH, Zhou L, Emerson DJ, Phyo SA, Titus KR, Gong W et al (2018) Disease-associated short tandem repeats co-localize with chromatin domain boundaries. Cell 175:224-238.e15. https:\/\/doi.org\/10.1016\/j.cell.2018.08.005","journal-title":"Cell"},{"key":"13888_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/ng0897-402","volume":"16","author":"TR Klesert","year":"1997","unstructured":"Klesert TR, Otten AD, Bird TD, Tapscott SJ (1997) Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat Genet 16:402\u2013406. https:\/\/doi.org\/10.1038\/ng0897-402","journal-title":"Nat Genet"},{"key":"13888_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/cge.12954","volume":"92","author":"M Santoro","year":"2017","unstructured":"Santoro M, Masciullo M, Silvestri G, Novelli G, Botta A (2017) Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis. Clin Genet 92:355\u2013364. https:\/\/doi.org\/10.1111\/cge.12954","journal-title":"Clin Genet"},{"key":"13888_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212594","volume":"22","author":"VV Visconti","year":"2021","unstructured":"Visconti VV, Centofanti F, Fittipaldi S, Macr\u00ec E, Novelli G, Botta A (2021) Epigenetics of myotonic dystrophies: a mini review. Int J Mol Sci 22:12594. https:\/\/doi.org\/10.3390\/ijms222212594","journal-title":"Int J Mol Sci"},{"key":"13888_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2511","author":"J Hartman","year":"2024","unstructured":"Hartman J, Patki T, Johnson NE (2024) Diagnosis and management of myotonic dystrophy type 1. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.2511","journal-title":"JAMA"},{"key":"13888_CR68","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00415-013-6993-0","volume":"260","author":"JE Hilbert","year":"2013","unstructured":"Hilbert JE, Ashizawa T, Day JW, Luebbe EA, Martens WB, McDermott MP et al (2013) Diagnostic odyssey of patients with myotonic dystrophy. J Neurol 260:2497\u20132504. https:\/\/doi.org\/10.1007\/s00415-013-6993-0","journal-title":"J Neurol"},{"key":"13888_CR69","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ejhg.2012.108","volume":"20","author":"E-J Kamsteeg","year":"2012","unstructured":"Kamsteeg E-J, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley MF et al (2012) Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet 20:1203\u20131208. https:\/\/doi.org\/10.1038\/ejhg.2012.108","journal-title":"Eur J Hum Genet"},{"key":"13888_CR70","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4081\/918","volume":"48","author":"R Cardani","year":"2004","unstructured":"Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G (2004) Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 48:437\u2013442","journal-title":"Eur J Histochem"},{"key":"13888_CR71","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/gtmb.2015.0135","volume":"19","author":"R Valaperta","year":"2015","unstructured":"Valaperta R, Lombardi F, Cardani R, Fossati B, Brigonzi E, Merli I et al (2015) Development and validation of a new molecular diagnostic assay for detection of myotonic dystrophy type 2. Genet Test Mol Biomark 19:703\u2013709. https:\/\/doi.org\/10.1089\/gtmb.2015.0135","journal-title":"Genet Test Mol Biomark"},{"key":"13888_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810491","author":"L Timchenko","year":"2022","unstructured":"Timchenko L (2022) Development of therapeutic approaches for myotonic dystrophies type 1 and type 2. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231810491","journal-title":"Int J Mol Sci"},{"key":"13888_CR73","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/nox242","volume":"20","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM (2017) The FDA NIH biomarkers, EndpointS, and other tools (BEST) resource in neuro-oncology. Neuro-oncol 20:1162\u20131172. https:\/\/doi.org\/10.1093\/neuonc\/nox242","journal-title":"Neuro-oncol"},{"key":"13888_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med 243:213\u2013221. https:\/\/doi.org\/10.1177\/1535370217750088","journal-title":"Exp Biol Med"},{"key":"13888_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1373\/clinchem.2015.252163","volume":"62","author":"MS Pepe","year":"2016","unstructured":"Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J (2016) Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem 62:737\u2013742. https:\/\/doi.org\/10.1373\/clinchem.2015.252163","journal-title":"Clin Chem"},{"key":"13888_CR76","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/acn3.496","volume":"4","author":"J-Y Hogrel","year":"2017","unstructured":"Hogrel J-Y, Ollivier G, Ledoux I, H\u00e9bert LJ, Eymard B, Puymirat J et al (2017) Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1. Ann Clin Transl Neurol 4:921\u2013925. https:\/\/doi.org\/10.1002\/acn3.496","journal-title":"Ann Clin Transl Neurol"},{"key":"13888_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130352","volume":"10","author":"C Schneider-Gold","year":"2015","unstructured":"Schneider-Gold C, Bellenberg B, Prehn C, Krogias C, Schneider R, Klein J et al (2015) Cortical and subcortical grey and white matter atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive impairment, depression and daytime sleepiness. PLoS ONE 10:e0130352. https:\/\/doi.org\/10.1371\/journal.pone.0130352","journal-title":"PLoS ONE"},{"key":"13888_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/16501970500477967","volume":"38","author":"G Antonini","year":"2006","unstructured":"Antonini G, Soscia F, Giubilei F, De Carolis A, Gragnani F, Morino S et al (2006) Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med 38:181\u2013185. https:\/\/doi.org\/10.1080\/16501970500477967","journal-title":"J Rehabil Med"},{"key":"13888_CR79","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaneurol.2014.130","volume":"71","author":"L Serra","year":"2014","unstructured":"Serra L, Silvestri G, Petrucci A, Basile B, Masciullo M, Makovac E et al (2014) Abnormal functional brain connectivity and personality traits in myotonic dystrophy type 1. JAMA Neurol 71:603\u2013611. https:\/\/doi.org\/10.1001\/jamaneurol.2014.130","journal-title":"JAMA Neurol"},{"key":"13888_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0304-3940(03)00740-7","volume":"348","author":"J Kassubek","year":"2003","unstructured":"Kassubek J, Juengling FD, Hoffmann S, Rosenbohm A, Kurt A, Jurkat-Rott K et al (2003) Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett 348:73\u201376. https:\/\/doi.org\/10.1016\/S0304-3940(03)00740-7","journal-title":"Neurosci Lett"},{"key":"13888_CR81","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cortex.2017.08.008","volume":"95","author":"K Okkersen","year":"2017","unstructured":"Okkersen K, Buskes M, Groenewoud J, Kessels RPC, Knoop H, van Engelen B et al (2017) The cognitive profile of myotonic dystrophy type 1: a systematic review and meta-analysis. Cortex 95:143\u2013155. https:\/\/doi.org\/10.1016\/j.cortex.2017.08.008","journal-title":"Cortex"},{"key":"13888_CR82","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00415-022-11165-0","volume":"269","author":"TF Nicoletti","year":"2022","unstructured":"Nicoletti TF, Rossi S, Vita MG, Perna A, Guerrera G, Lino F et al (2022) Elevated serum neurofilament light chain (NfL) as a potential biomarker of neurological involvement in myotonic dystrophy type 1 (DM1). J Neurol 269:5085\u20135092. https:\/\/doi.org\/10.1007\/s00415-022-11165-0","journal-title":"J Neurol"},{"key":"13888_CR83","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/hmg\/ddaf002","volume":"34","author":"K Jennings","year":"2025","unstructured":"Jennings K, Lindquist D, Poonia A, Schoser B, Schneider-Gold C, Timchenko NA et al (2025) The role of CNBP in brain atrophy and its targeting in myotonic dystrophy type 2. Hum Mol Genet 34:512\u2013522. https:\/\/doi.org\/10.1093\/hmg\/ddaf002","journal-title":"Hum Mol Genet"},{"key":"13888_CR84","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/ene.15174","volume":"29","author":"M Garibaldi","year":"2022","unstructured":"Garibaldi M, Nicoletti T, Bucci E, Fionda L, Leonardi L, Morino S et al (2022) Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): refining muscle involvement and implications for clinical trials. Eur J Neurol 29:843\u2013854. https:\/\/doi.org\/10.1111\/ene.15174","journal-title":"Eur J Neurol"},{"key":"13888_CR85","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1007\/s00415-024-12544-5","volume":"271","author":"L Fionda","year":"2024","unstructured":"Fionda L, Leonardi L, Tufano L, Lauletta A, Morino S, Merlonghi G et al (2024) Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study. J Neurol 271:5864\u20135874. https:\/\/doi.org\/10.1007\/s00415-024-12544-5","journal-title":"J Neurol"},{"key":"13888_CR86","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1212\/wnl.0000000000211488","volume":"104","author":"L Hinkley","year":"2025","unstructured":"Hinkley L, Wagner K, Jacobs MA, Leung D (2025) Clinical and imaging biomarkers in myotonic dystrophy type 2 (P2-11.022). Neurology 104:4157. https:\/\/doi.org\/10.1212\/wnl.0000000000211488","journal-title":"Neurology"},{"key":"13888_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/tomography11120136","volume":"11","author":"S Eierle","year":"2025","unstructured":"Eierle S, Taivassalo T, Park H, Cooke KD, Moslemi Z, Forbes SC et al (2025) Quantitative magnetic resonance imaging of the forearm in myotonic dystrophy type 1. Tomography 11:136. https:\/\/doi.org\/10.3390\/tomography11120136","journal-title":"Tomography"},{"key":"13888_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1525952","author":"V Kokosova","year":"2025","unstructured":"Kokosova V, Krkoska P, Vlazna D, Sladeckova M, Dostal M, Kerkovsky M et al (2025) Quantitative magnetic resonance imaging parameters of lumbar paraspinal muscle impairment in myotonic dystrophy type 2 and their evolution with aging. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2025.1525952","journal-title":"Front Neurol"},{"key":"13888_CR89","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ana.23992","volume":"74","author":"M Nakamori","year":"2013","unstructured":"Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S et al (2013) Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol 74:862\u2013872. https:\/\/doi.org\/10.1002\/ana.23992","journal-title":"Ann Neurol"},{"key":"13888_CR90","doi-asserted-by":"publisher","first-page":"e93983","DOI":"10.1371\/journal.pone.0093983","volume":"9","author":"A Perfetti","year":"2014","unstructured":"Perfetti A, Greco S, Fasanaro P, Bugiardini E, Cardani R, Garcia JM et al (2014) Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2. PLoS ONE 9:e93983\u2013e93983. https:\/\/doi.org\/10.1371\/journal.pone.0093983","journal-title":"PLoS ONE"},{"key":"13888_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","volume":"10","author":"N Charlet-B","year":"2002","unstructured":"Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10:45\u201353. https:\/\/doi.org\/10.1016\/S1097-2765(02)00572-5","journal-title":"Mol Cell"},{"key":"13888_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s1097-2765(02)00563-4","volume":"10","author":"A Mankodi","year":"2002","unstructured":"Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT et al (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10:35\u201344. https:\/\/doi.org\/10.1016\/s1097-2765(02)00563-4","journal-title":"Mol Cell"},{"key":"13888_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11067","author":"F Freyermuth","year":"2016","unstructured":"Freyermuth F, Rau F, Kokunai Y, Linke T, Sellier C, Nakamori M et al (2016) Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms11067","journal-title":"Nat Commun"},{"key":"13888_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00992","author":"F Bos\u00e8","year":"2019","unstructured":"Bos\u00e8 F, Renna LV, Fossati B, Arpa G, Labate V, Milani V et al (2019) TNNT2 missplicing in skeletal muscle as a cardiac biomarker in myotonic dystrophy type 1 but not in myotonic dystrophy type 2. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2019.00992","journal-title":"Front Neurol"},{"key":"13888_CR95","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nm.2374","volume":"17","author":"C Fugier","year":"2011","unstructured":"Fugier C, Klein AF, Hammer C, Vassilopoulos S, Ivarsson Y, Toussaint A et al (2011) Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 17:720\u2013725. https:\/\/doi.org\/10.1038\/nm.2374","journal-title":"Nat Med"},{"key":"13888_CR96","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/hmg\/ddr568","volume":"21","author":"ZZ Tang","year":"2011","unstructured":"Tang ZZ, Yarotskyy V, Wei L, Sobczak K, Nakamori M, Eichinger K et al (2011) Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. Hum Mol Genet 21:1312\u20131324. https:\/\/doi.org\/10.1093\/hmg\/ddr568","journal-title":"Hum Mol Genet"},{"key":"13888_CR97","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.nbd.2011.08.010","volume":"45","author":"F Rinaldi","year":"2012","unstructured":"Rinaldi F, Terracciano C, Pisani V, Massa R, Loro E, Vergani L et al (2012) Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues. Neurobiol Dis 45:264\u2013271. https:\/\/doi.org\/10.1016\/j.nbd.2011.08.010","journal-title":"Neurobiol Dis"},{"key":"13888_CR98","doi-asserted-by":"publisher","first-page":"e48825","DOI":"10.1371\/journal.pone.0048825","volume":"7","author":"SP Jog","year":"2012","unstructured":"Jog SP, Paul S, Dansithong W, Tring S, Comai L, Reddy S (2012) RNA splicing is responsive to MBNL1 dose. PLoS ONE 7:e48825\u2013e48825. https:\/\/doi.org\/10.1371\/journal.pone.0048825","journal-title":"PLoS ONE"},{"key":"13888_CR99","doi-asserted-by":"publisher","first-page":"e1006316","DOI":"10.1371\/journal.pgen.1006316","volume":"12","author":"SD Wagner","year":"2016","unstructured":"Wagner SD, Struck AJ, Gupta R, Farnsworth DR, Mahady AE, Eichinger K et al (2016) Dose-dependent regulation of alternative splicing by MBNL proteins reveals biomarkers for myotonic dystrophy. PLoS Genet 12:e1006316\u2013e1006316. https:\/\/doi.org\/10.1371\/journal.pgen.1006316","journal-title":"PLoS Genet"},{"key":"13888_CR100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","volume":"22","author":"CA Thornton","year":"2023","unstructured":"Thornton CA, Moxley RT, Eichinger K, Heatwole C, Mignon L, Arnold WD et al (2023) Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial. Lancet Neurol 22:218\u2013228. https:\/\/doi.org\/10.1016\/S1474-4422(23)00001-7","journal-title":"Lancet Neurol"},{"issue":"4","key":"13888_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/jci185426","volume":"135","author":"M Provenzano","year":"2025","unstructured":"Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman JM, Jones A et al (2025) The splice index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. J Clin Invest 135(4):e185426. https:\/\/doi.org\/10.1172\/jci185426","journal-title":"J Clin Invest"},{"key":"13888_CR102","unstructured":"Safety, tolerability, pharmacodynamic, efficacy, and pharmacokinetic study of DYNE-101 in participants with myotonic dystrophy type 1 (ACHIEVE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05481879"},{"key":"13888_CR103","unstructured":"Study of AOC 1001 in adult myotonic dystrophy (DM1) patients (MARINA). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05027269"},{"key":"13888_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.072","volume":"43","author":"D Wolf","year":"2024","unstructured":"Wolf D, Lilleker J, Bassez G, Diaz-Manera J, Kools J, Pane M et al (2024) 221P initial data from the achieve trial of DYNE-101 in adults with myotonic dystrophy type 1 (DM1). Neuromuscul Disord 43:104441.63. https:\/\/doi.org\/10.1016\/j.nmd.2024.07.072","journal-title":"Neuromuscul Disord"},{"key":"13888_CR105","doi-asserted-by":"publisher","DOI":"10.1177\/22143602251365101","author":"JA Berglund","year":"2025","unstructured":"Berglund JA, Novack A, Ivanovska Holder I, Ray S, Johnson NE (2025) Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy type 1 (DM1) clinical trials. J Neuromuscul Dis. https:\/\/doi.org\/10.1177\/22143602251365101","journal-title":"J Neuromuscul Dis"},{"key":"13888_CR106","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa2407326","volume":"394","author":"NE Johnson","year":"2026","unstructured":"Johnson NE, Tai L-J, Hamel JI, Day JW, Statland JM, Soltanzadeh P et al (2026) An antibody\u2013oligonucleotide conjugate for myotonic dystrophy type 1. N Engl J Med 394:763\u2013772. https:\/\/doi.org\/10.1056\/NEJMoa2407326","journal-title":"N Engl J Med"},{"key":"13888_CR107","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3727\/000000006781510705","volume":"13","author":"A Botta","year":"2007","unstructured":"Botta A, Vallo L, Rinaldi F, Bonifazi E, Amati F, Biancolella M et al (2007) Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr 13:339\u2013351. https:\/\/doi.org\/10.3727\/000000006781510705","journal-title":"Gene Expr"},{"key":"13888_CR108","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/biomedicines13030606","volume":"13","author":"V Todorow","year":"2025","unstructured":"Todorow V, Hintze S, Schoser B, Meinke P (2025) Comparative analysis of splicing alterations in three muscular dystrophies. Biomedicines 13:606\u2013606. https:\/\/doi.org\/10.3390\/biomedicines13030606","journal-title":"Biomedicines"},{"key":"13888_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168607","volume":"22","author":"V Todorow","year":"2021","unstructured":"Todorow V, Hintze S, Kerr ARW, Hehr A, Schoser B, Meinke P (2021) Transcriptome analysis in a primary human muscle cell differentiation model for myotonic dystrophy type 1. Int J Mol Sci 22:8607. https:\/\/doi.org\/10.3390\/ijms22168607","journal-title":"Int J Mol Sci"},{"key":"13888_CR110","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JND-221645","volume":"10","author":"A Aoussim","year":"2023","unstructured":"Aoussim A, L\u00e9gar\u00e9 C, Roussel M-P, Madore A-M, Morissette MC, Laprise C et al (2023) Towards the identification of biomarkers for muscle function improvement in myotonic dystrophy type 1. J Neuromuscul Dis 10:1041\u20131053. https:\/\/doi.org\/10.3233\/JND-221645","journal-title":"J Neuromuscul Dis"},{"key":"13888_CR111","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/hmg\/dds478","volume":"22","author":"JM Fernandez-Costa","year":"2013","unstructured":"Fernandez-Costa JM, Garcia-Lopez A, Zu\u00f1iga S, Fernandez-Pedrosa V, Felipo-Benavent A, Mata M et al (2013) Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients. Hum Mol Genet 22:704\u2013716. https:\/\/doi.org\/10.1093\/hmg\/dds478","journal-title":"Hum Mol Genet"},{"key":"13888_CR112","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1172\/jci89616","volume":"127","author":"M Brockhoff","year":"2017","unstructured":"Brockhoff M, Rion N, Chojnowska K, Wiktorowicz T, Eickhorst C, Erne B et al (2017) Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type I. J Clin Invest 127:549\u2013563. https:\/\/doi.org\/10.1172\/jci89616","journal-title":"J Clin Invest"},{"key":"13888_CR113","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1093\/hmg\/ddy192","volume":"27","author":"GR Morriss","year":"2018","unstructured":"Morriss GR, Rajapakshe K, Huang S, Coarfa C, Cooper TA (2018) Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet 27:2789\u20132804. https:\/\/doi.org\/10.1093\/hmg\/ddy192","journal-title":"Hum Mol Genet"},{"key":"13888_CR114","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/cdd.2008.131","volume":"16","author":"MC Maiuri","year":"2008","unstructured":"Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R et al (2008) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16:87\u201393. https:\/\/doi.org\/10.1038\/cdd.2008.131","journal-title":"Cell Death Differ"},{"key":"13888_CR115","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.chom.2016.10.012","volume":"20","author":"V Oikonomou","year":"2016","unstructured":"Oikonomou V, Moretti S, Renga G, Galosi C, Borghi M, Pariano M et al (2016) Noncanonical fungal autophagy inhibits inflammation in response to IFN-\u03b3 via DAPK1. Cell Host Microbe 20:744\u2013757. https:\/\/doi.org\/10.1016\/j.chom.2016.10.012","journal-title":"Cell Host Microbe"},{"key":"13888_CR116","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/med.21518","volume":"39","author":"AK Farag","year":"2019","unstructured":"Farag AK, Roh EJ (2019) Death-associated protein kinase (DAPK) family modulators: current and future therapeutic outcomes. Med Res Rev Wiley 39:349\u2013385. https:\/\/doi.org\/10.1002\/med.21518","journal-title":"Med Res Rev Wiley"},{"key":"13888_CR117","doi-asserted-by":"publisher","first-page":"1022640","DOI":"10.3389\/fgene.2022.1022640","volume":"13","author":"M Hu","year":"2022","unstructured":"Hu M, Ge M-R, Li H-X, Zhang B, Li G (2022) Identification of DAPK1 as an autophagy-related biomarker for myotonic dystrophy type 1. Front Genet Frontiers Media 13:1022640\u20131022640. https:\/\/doi.org\/10.3389\/fgene.2022.1022640","journal-title":"Front Genet Frontiers Media"},{"key":"13888_CR118","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/wco.0000000000000359","volume":"29","author":"P Meinke","year":"2016","unstructured":"Meinke P, Schirmer EC (2016) The increasing relevance of nuclear envelope myopathies. Curr Opin Neurol 29:651\u2013661. https:\/\/doi.org\/10.1097\/wco.0000000000000359","journal-title":"Curr Opin Neurol"},{"key":"13888_CR119","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3389\/fphys.2018.01532","volume":"9","author":"S Hintze","year":"2018","unstructured":"Hintze S, Knaier L, Limmer S, Schoser B, Meinke P (2018) Nuclear envelope transmembrane proteins in myotonic dystrophy type 1. Front Physiol Front Media 9:1532\u20131532. https:\/\/doi.org\/10.3389\/fphys.2018.01532","journal-title":"Front Physiol Front Media"},{"key":"13888_CR120","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fneur.2018.00601","volume":"9","author":"P Meinke","year":"2018","unstructured":"Meinke P, Hintze S, Limmer S, Schoser B (2018) Myotonic dystrophy: a progeroid disease? Front Neurol 9:601. https:\/\/doi.org\/10.3389\/fneur.2018.00601","journal-title":"Front Neurol"},{"key":"13888_CR121","doi-asserted-by":"publisher","first-page":"1007331","DOI":"10.3389\/fcell.2022.1007331","volume":"10","author":"V Todorow","year":"2022","unstructured":"Todorow V, Hintze S, Schoser B, Meinke P (2022) Nuclear envelope transmembrane proteins involved in genome organization are misregulated in myotonic dystrophy type 1 muscle. Front Cell Dev Biol 10:1007331. https:\/\/doi.org\/10.3389\/fcell.2022.1007331","journal-title":"Front Cell Dev Biol"},{"key":"13888_CR122","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.nbd.2010.01.017","volume":"38","author":"F Rusconi","year":"2010","unstructured":"Rusconi F, Mancinelli E, Colombo G, Cardani R, Da Riva L, Bongarzone I et al (2010) Proteome profile in myotonic dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiol Dis Academic Press 38:273\u2013280. https:\/\/doi.org\/10.1016\/j.nbd.2010.01.017","journal-title":"Neurobiol Dis Academic Press"},{"issue":"1","key":"13888_CR123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-023-02673-y","volume":"147","author":"F Kleefeld","year":"2024","unstructured":"Kleefeld F, Horvath R, Pinal-Fernandez I, Mammen AL, Casal-Dominguez M, Hathazi D et al (2024) Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2. Acta Neuropathol (Berl) 147(1):19. https:\/\/doi.org\/10.1007\/s00401-023-02673-y","journal-title":"Acta Neuropathol (Berl)"},{"key":"13888_CR124","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0361-9230(01)00653-0","volume":"56","author":"G Siciliano","year":"2001","unstructured":"Siciliano G, Mancuso M, Tedeschi D, Manca ML, Renna MR, Lombardi V et al (2001) Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull 56:405\u2013410. https:\/\/doi.org\/10.1016\/S0361-9230(01)00653-0","journal-title":"Brain Res Bull"},{"key":"13888_CR125","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1073\/pnas.1013343108","volume":"108","author":"T Zu","year":"2011","unstructured":"Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD et al (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 108:260\u2013265. https:\/\/doi.org\/10.1073\/pnas.1013343108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13888_CR126","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.3390\/jcm10235520","volume":"10","author":"E Koehorst","year":"2021","unstructured":"Koehorst E, N\u00fa\u00f1ez-Manch\u00f3n J, Ballester-L\u00f3pez A, Almendrote M, Lucente G, Arbex A et al (2021) Characterization of RAN translation and antisense transcription in primary cell cultures of patients with myotonic dystrophy type 1. J Clin Med 10:5520. https:\/\/doi.org\/10.3390\/jcm10235520","journal-title":"J Clin Med"},{"key":"13888_CR127","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.neuron.2017.08.039","volume":"95","author":"T Zu","year":"2017","unstructured":"Zu T, Cleary JD, Liu Y, Ba\u00f1ez-Coronel M, Bubenik JL, Ayhan F et al (2017) RAN translation regulated by muscleblind proteins in myotonic dystrophy type 2. Neuron 95:1292-1305.e5. https:\/\/doi.org\/10.1016\/j.neuron.2017.08.039","journal-title":"Neuron"},{"key":"13888_CR128","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","volume":"77","author":"PEA Ash","year":"2013","unstructured":"Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin W-L, DeJesus-Hernandez M et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS. Neuron 77:639\u2013646. https:\/\/doi.org\/10.1016\/j.neuron.2013.02.004","journal-title":"Neuron"},{"key":"13888_CR129","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neuron.2017.02.046","volume":"94","author":"T Ishiguro","year":"2017","unstructured":"Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A et al (2017) Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in SCA31. Neuron 94:108-124.e7. https:\/\/doi.org\/10.1016\/j.neuron.2017.02.046","journal-title":"Neuron"},{"key":"13888_CR130","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ana.24800","volume":"80","author":"A Krans","year":"2016","unstructured":"Krans A, Kearse MG, Todd PK (2016) Repeat-associated non-AUG translation from antisense CCG repeats in Fragile X tremor\/ataxia syndrome. Ann Neurol 80:871\u2013881. https:\/\/doi.org\/10.1002\/ana.24800","journal-title":"Ann Neurol"},{"key":"13888_CR131","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00018-018-2940-7","volume":"76","author":"M Pu","year":"2018","unstructured":"Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y et al (2018) Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 76:441\u2013451. https:\/\/doi.org\/10.1007\/s00018-018-2940-7","journal-title":"Cell Mol Life Sci"},{"key":"13888_CR132","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843\u2013854. https:\/\/doi.org\/10.1016\/0092-8674(93)90529-y","journal-title":"Cell"},{"key":"13888_CR133","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ncrna.2018.12.001","volume":"4","author":"E De Paola","year":"2018","unstructured":"De Paola E, Verdile V, Paronetto MP (2018) Dysregulation of microRNA metabolism in motor neuron diseases: novel biomarkers and potential therapeutics. Non-Coding RNA Res 4:15\u201322. https:\/\/doi.org\/10.1016\/j.ncrna.2018.12.001","journal-title":"Non-Coding RNA Res"},{"key":"13888_CR134","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.3390\/ijms22115673","volume":"22","author":"C Malacarne","year":"2021","unstructured":"Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F et al (2021) Dysregulation of muscle-specific MicroRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients. Int J Mol Sci 22:5673. https:\/\/doi.org\/10.3390\/ijms22115673","journal-title":"Int J Mol Sci"},{"key":"13888_CR135","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nmd.2010.11.012","volume":"21","author":"R Perbellini","year":"2011","unstructured":"Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G et al (2011) Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 21:81\u201388. https:\/\/doi.org\/10.1016\/j.nmd.2010.11.012","journal-title":"Neuromuscul Disord"},{"key":"13888_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039732","volume":"7","author":"S Greco","year":"2012","unstructured":"Greco S, Perfetti A, Fasanaro P, Cardani R, Capogrossi MC, Meola G et al (2012) Deregulated microRNAs in myotonic dystrophy type 2. PLoS ONE 7:e39732. https:\/\/doi.org\/10.1371\/journal.pone.0039732","journal-title":"PLoS ONE"},{"key":"13888_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-48","volume":"8","author":"S Gambardella","year":"2010","unstructured":"Gambardella S, Rinaldi F, Lepore SM, Viola A, Loro E, Angelini C et al (2010) Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med 8:48. https:\/\/doi.org\/10.1186\/1479-5876-8-48","journal-title":"J Transl Med"},{"key":"13888_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102584","volume":"36","author":"N Moreno","year":"2025","unstructured":"Moreno N, Sabater-Arcis M, Espinosa-Espinosa J, Mulet-Rivero L, Garc\u00eda-Espa\u00f1a E, Gonz\u00e1lez-Garc\u00eda J et al (2025) miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2\/miR-7 pathogenesis axis in myotonic dystrophy. Mol Ther Nucleic Acids 36:102584. https:\/\/doi.org\/10.1016\/j.omtn.2025.102584","journal-title":"Mol Ther Nucleic Acids"},{"key":"13888_CR139","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10072-017-2811-2","volume":"38","author":"C Fritegotto","year":"2017","unstructured":"Fritegotto C, Ferrati C, Pegoraro V, Angelini C (2017) Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. Neurol Sci 38:619\u2013625. https:\/\/doi.org\/10.1007\/s10072-017-2811-2","journal-title":"Neurol Sci"},{"key":"13888_CR140","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","volume":"9","author":"E Cerro-Herreros","year":"2018","unstructured":"Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa JM, Moreno N, Perez-Alonso M, Llamusi B et al (2018) miR-23b and miR-218 silencing increase muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models. Nat Commun 9:2482. https:\/\/doi.org\/10.1038\/s41467-018-04892-4","journal-title":"Nat Commun"},{"key":"13888_CR141","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn6525","volume":"10","author":"E Cerro-Herreros","year":"2024","unstructured":"Cerro-Herreros E, N\u00fa\u00f1ez-Manch\u00f3n J, Naldaiz-Gastesi N, Carrascosa-S\u00e0ez M, Garc\u00eda-Rey A, Losilla DP et al (2024) AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action. Sci Adv 10:eadn6525. https:\/\/doi.org\/10.1126\/sciadv.adn6525","journal-title":"Sci Adv"},{"key":"13888_CR142","doi-asserted-by":"publisher","first-page":"12055","DOI":"10.1093\/nar\/gkae774","volume":"52","author":"A Piasecka","year":"2024","unstructured":"Piasecka A, Szcze\u015bniak MW, Sekrecki M, Kajdasz A, Sznajder \u0141J, Baud A et al (2024) MBNL splicing factors regulate the microtranscriptome of skeletal muscles. Nucleic Acids Res 52:12055\u201312073. https:\/\/doi.org\/10.1093\/nar\/gkae774","journal-title":"Nucleic Acids Res"},{"key":"13888_CR143","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.omtn.2021.07.017","volume":"26","author":"E Cerro-Herreros","year":"2021","unstructured":"Cerro-Herreros E, Gonz\u00e1lez-Mart\u00ednez I, Moreno N, Espinosa-Espinosa J, Fern\u00e1ndez-Costa JM, Colom-Rodrigo A et al (2021) Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy. Mol Ther Nucleic Acids 26:174\u2013191. https:\/\/doi.org\/10.1016\/j.omtn.2021.07.017","journal-title":"Mol Ther Nucleic Acids"},{"key":"13888_CR144","unstructured":"Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1"},{"key":"13888_CR145","unstructured":"Study of ATX-01 in Participants with DM1 (ArthemiR). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06300307"},{"key":"13888_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/srep38174","volume":"6","author":"A Perfetti","year":"2016","unstructured":"Perfetti A, Greco S, Cardani R, Fossati B, Cuomo G, Valaperta R et al (2016) Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. Sci Rep 6:43074. https:\/\/doi.org\/10.1038\/srep38174","journal-title":"Sci Rep"},{"key":"13888_CR147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125341","volume":"10","author":"A Koutsoulidou","year":"2015","unstructured":"Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ et al (2015) Elevated muscle-specific miRNAs in serum of myotonic dystrophy patients relate to muscle disease progress. PLoS ONE 10:e0125341. https:\/\/doi.org\/10.1371\/journal.pone.0125341","journal-title":"PLoS ONE"},{"key":"13888_CR148","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1093\/hmg\/ddx212","volume":"26","author":"A Koutsoulidou","year":"2017","unstructured":"Koutsoulidou A, Photiades M, Kyriakides TC, Georgiou K, Prokopi M, Kapnisis K et al (2017) Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress. Hum Mol Genet 26:3285\u20133302. https:\/\/doi.org\/10.1093\/hmg\/ddx212","journal-title":"Hum Mol Genet"},{"key":"13888_CR149","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtm.2021.09.007","volume":"23","author":"D Koutalianos","year":"2021","unstructured":"Koutalianos D, Koutsoulidou A, Mytidou C, Kakouri AC, Oulas A, Tomazou M et al (2021) miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1. Mol Ther Methods Clin Dev 23:169\u2013183. https:\/\/doi.org\/10.1016\/j.omtm.2021.09.007","journal-title":"Mol Ther Methods Clin Dev"},{"key":"13888_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081938","volume":"20","author":"C Voellenkle","year":"2019","unstructured":"Voellenkle C, Perfetti A, Carrara M, Fuschi P, Renna LV, Longo M et al (2019) Dysregulation of circular RNAs in myotonic dystrophy type 1. Int J Mol Sci 20:1938. https:\/\/doi.org\/10.3390\/ijms20081938","journal-title":"Int J Mol Sci"},{"key":"13888_CR151","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.3390\/ijms20184385","volume":"20","author":"K Czubak","year":"2019","unstructured":"Czubak K, Sedehizadeh S, Kozlowski P, Wojciechowska M (2019) An overview of circular RNAs and their implications in myotonic dystrophy. Int J Mol Sci 20:4385\u20134385. https:\/\/doi.org\/10.3390\/ijms20184385","journal-title":"Int J Mol Sci"},{"key":"13888_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00649","author":"K Czubak","year":"2019","unstructured":"Czubak K, Taylor K, Piasecka A, Sobczak K, Kozlowska K, Philips A et al (2019) Global increase in circular RNA levels in myotonic dystrophy. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2019.00649","journal-title":"Front Genet"},{"key":"13888_CR153","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00439-025-02729-x","volume":"144","author":"A Srinivasan","year":"2025","unstructured":"Srinivasan A, Magner D, Koz\u0142owski P, Philips A, Kajdasz A, Wojciechowski P et al (2025) Global dysregulation of circular RNAs in frontal cortex and whole blood from DM1 and DM2. Hum Genet 144:417\u2013432. https:\/\/doi.org\/10.1007\/s00439-025-02729-x","journal-title":"Hum Genet"},{"key":"13888_CR154","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100836","author":"IL Patop","year":"2019","unstructured":"Patop IL, W\u00fcst S, Kadener S (2019) Past, present, and future of circRNAs. EMBO J. https:\/\/doi.org\/10.15252\/embj.2018100836","journal-title":"EMBO J"},{"key":"13888_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113454","volume":"19","author":"S Greco","year":"2018","unstructured":"Greco S, Cardinali B, Falcone G, Martelli F (2018) Circular RNAs in muscle function and disease. Int J Mol Sci 19:3454. https:\/\/doi.org\/10.3390\/ijms19113454","journal-title":"Int J Mol Sci"},{"key":"13888_CR156","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li X, Yang L, Chen L-L (2018) The biogenesis, functions, and challenges of circular RNAs. Mol Cell 71:428\u2013442. https:\/\/doi.org\/10.1016\/j.molcel.2018.06.034","journal-title":"Mol Cell"},{"key":"13888_CR157","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.01.010","volume":"187","author":"B Han","year":"2018","unstructured":"Han B, Chao J, Yao H (2018) Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther 187:31\u201344. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.010","journal-title":"Pharmacol Ther"},{"key":"13888_CR158","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384\u2013388. https:\/\/doi.org\/10.1038\/nature11993","journal-title":"Nature"},{"key":"13888_CR159","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.omtn.2025.102646","volume":"36","author":"D Baci","year":"2025","unstructured":"Baci D, Tastsoglou S, Provenzano C, Perfetti A, Izzo M, Lisanti M et al (2025) circARHGAP10 as a candidate biomarker and therapeutic target in myotonic dystrophy type 1. Mol Ther Nucleic Acids 36:102646\u2013102646. https:\/\/doi.org\/10.1016\/j.omtn.2025.102646","journal-title":"Mol Ther Nucleic Acids"},{"key":"13888_CR160","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.omtm.2020.05.017","volume":"18","author":"A Koutsoulidou","year":"2020","unstructured":"Koutsoulidou A, Phylactou LA (2020) Circulating biomarkers in muscular dystrophies: disease and therapy monitoring. Mol Ther Methods Clin Dev 18:230\u2013239. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"13888_CR161","first-page":"185","volume":"161","author":"R Falsaperla","year":"2010","unstructured":"Falsaperla R, Parano E, Practic\u00f2 AD, Pavone P (2010) HyperCKemia as a biomarker for muscular diseases. Clin Ter 161(2):185","journal-title":"Clin Ter"},{"key":"13888_CR162","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/s1474-4422(12)70204-1","volume":"11","author":"B Udd","year":"2012","unstructured":"Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891\u2013905. https:\/\/doi.org\/10.1016\/s1474-4422(12)70204-1","journal-title":"Lancet Neurol"},{"key":"13888_CR163","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.880100105","volume":"10","author":"MJ Jackson","year":"1987","unstructured":"Jackson MJ, Round JM, Newham DJ, Edwards RHT (1987) An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy. Muscle Nerve 10:15\u201321. https:\/\/doi.org\/10.1002\/mus.880100105","journal-title":"Muscle Nerve"},{"key":"13888_CR164","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jb\/46.1.103","volume":"46","author":"S Ebashi","year":"1959","unstructured":"Ebashi S, Toyokura Y, Momoi H, Sugita H (1959) High creatine phosphokinase activity of sera with progressive muscular dystrophy. J Biochem (Tokyo) 46:103\u2013104. https:\/\/doi.org\/10.1093\/jb\/46.1.103","journal-title":"J Biochem (Tokyo)"},{"key":"13888_CR165","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/mus.27760","volume":"67","author":"AM Zygmunt","year":"2022","unstructured":"Zygmunt AM, Wong BL, Horn PS, Lambert J, Bange JE, Rybalsky I et al (2022) A longitudinal study of creatine kinase and creatinine levels in Duchenne muscular dystrophy. Muscle Nerve 67:138\u2013145. https:\/\/doi.org\/10.1002\/mus.27760","journal-title":"Muscle Nerve"},{"key":"13888_CR166","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/mus.27917","volume":"68","author":"D Varga","year":"2023","unstructured":"Varga D, Perecz B, F\u00fcl\u00f6p K, Sipos A, Janszky JV, Hajd\u00fa N et al (2023) Urinary titin in myotonic dystrophy type 1. Muscle Nerve 68:215\u2013218. https:\/\/doi.org\/10.1002\/mus.27917","journal-title":"Muscle Nerve"},{"key":"13888_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2019.01.001","volume":"90","author":"M Matsuo","year":"2019","unstructured":"Matsuo M, Awano H, Maruyama N, Nishio H (2019) Chapter one: titin fragment in urine\u2014a noninvasive biomarker of muscle degradation. Adv Clin Chem 90:1\u201323. https:\/\/doi.org\/10.1016\/bs.acc.2019.01.001","journal-title":"Adv Clin Chem"},{"key":"13888_CR168","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cca.2017.11.024","volume":"476","author":"H Awano","year":"2018","unstructured":"Awano H, Matsumoto M, Nagai M, Shirakawa T, Maruyama N, Iijima K et al (2018) Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients. Clin Chim Acta 476:111\u2013116. https:\/\/doi.org\/10.1016\/j.cca.2017.11.024","journal-title":"Clin Chim Acta"},{"key":"13888_CR169","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cca.2019.04.005","volume":"495","author":"T Misaka","year":"2019","unstructured":"Misaka T, Yoshihisa A, Takeishi Y (2019) Titin in muscular dystrophy and cardiomyopathy: urinary titin as a novel marker. Clin Chim Acta 495:123\u2013128. https:\/\/doi.org\/10.1016\/j.cca.2019.04.005","journal-title":"Clin Chim Acta"},{"key":"13888_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110760","volume":"26","author":"K Jennings","year":"2025","unstructured":"Jennings K, Tian C, Brown RL, Horn PS, Schoser B, Kushlaf H et al (2025) Elevated levels of active GSK3\u03b2 in the blood of patients with myotonic dystrophy type 1 correlate with muscle weakness. Int J Mol Sci 26:10760\u201310760. https:\/\/doi.org\/10.3390\/ijms262110760","journal-title":"Int J Mol Sci"},{"key":"13888_CR171","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"L Seren\u00f3","year":"2009","unstructured":"Seren\u00f3 L, Coma M, Rodr\u00edguez M, S\u00e1nchez-Ferrer P, S\u00e1nchez MB, Gich I et al (2009) A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359\u2013367. https:\/\/doi.org\/10.1016\/j.nbd.2009.05.025","journal-title":"Neurobiol Dis"},{"key":"13888_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53886-y","author":"BM Marcella","year":"2024","unstructured":"Marcella BM, Hockey BL, Braun JL, Whitley KC, Geromella MS, Baranowski RW et al (2024) GSK3 inhibition improves skeletal muscle function and whole-body metabolism in male mouse models of Duchenne muscular dystrophy. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-024-53886-y","journal-title":"Nat Commun"},{"key":"13888_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105081","volume":"22","author":"TM Mirzoev","year":"2021","unstructured":"Mirzoev TM, Sharlo KA, Shenkman BS (2021) The role of GSK-3\u03b2 in the regulation of protein turnover, myosin phenotype, and oxidative capacity in skeletal muscle under disuse conditions. Int J Mol Sci 22:5081. https:\/\/doi.org\/10.3390\/ijms22105081","journal-title":"Int J Mol Sci"},{"key":"13888_CR174","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1007\/s00415-023-11633-1","volume":"270","author":"CDL Nguyen","year":"2023","unstructured":"Nguyen CDL, Jimenez-Moreno AC, Merker M, Bowers CJ, Nikolenko N, Hentschel A et al (2023) Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and disease severity in myotonic dystrophy type 1. J Neurol 270:3138\u20133158. https:\/\/doi.org\/10.1007\/s00415-023-11633-1","journal-title":"J Neurol"},{"key":"13888_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032204","volume":"24","author":"S Rossi","year":"2023","unstructured":"Rossi S, Silvestri G (2023) Fluid biomarkers of central nervous system (CNS) involvement in myotonic dystrophy type 1 (DM1). Int J Mol Sci 24:2204. https:\/\/doi.org\/10.3390\/ijms24032204","journal-title":"Int J Mol Sci"},{"key":"13888_CR176","doi-asserted-by":"publisher","first-page":"e000615","DOI":"10.1136\/openhrt-2017-000615","volume":"4","author":"JE Ho","year":"2017","unstructured":"Ho JE, Shi L, Day SM, Colan SD, Russell MW, Towbin JA et al (2017) Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart 4:e000615\u2013e000615. https:\/\/doi.org\/10.1136\/openhrt-2017-000615","journal-title":"Open Heart"},{"key":"13888_CR177","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/circresaha.107.159517","volume":"102","author":"P Snider","year":"2008","unstructured":"Snider P, Hinton RB, Moreno-Rodriguez RA, Wang J, Rogers R, Lindsley AW et al (2008) Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 102:752\u2013760. https:\/\/doi.org\/10.1161\/circresaha.107.159517","journal-title":"Circ Res"},{"key":"13888_CR178","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.athoracsur.2009.07.038","volume":"88","author":"WE Stansfield","year":"2009","unstructured":"Stansfield WE, Andersen NM, Tang R-H, Selzman CH (2009) Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg 88:1916\u20131921. https:\/\/doi.org\/10.1016\/j.athoracsur.2009.07.038","journal-title":"Ann Thorac Surg"},{"key":"13888_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.791065","author":"E van der Plas","year":"2022","unstructured":"van der Plas E, Long JD, Koscik TR, Magnotta V, Monckton DG, Cumming SA et al (2022) Blood-based markers of neuronal injury in adult-onset myotonic dystrophy type 1. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.791065","journal-title":"Front Neurol"},{"key":"13888_CR180","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ene.12237","volume":"21","author":"S Peric","year":"2013","unstructured":"Peric S, Mandic\u2010Stojmenovic G, Markovic I, Stefanova G, Ilic V, Parojcic A et al (2013) Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1. Eur J Neurol 21:231\u2013237. https:\/\/doi.org\/10.1111\/ene.12237","journal-title":"Eur J Neurol"},{"key":"13888_CR181","doi-asserted-by":"publisher","first-page":"1709678","DOI":"10.3389\/fnins.2025.1709678","volume":"19","author":"M Zafarullah","year":"2025","unstructured":"Zafarullah M, Kamali T, Hagerman KA, Ghiglieri L, Duong T, Wang E et al (2025) Cerebrospinal fluid proteomic profiling reveals potential biomarkers and altered pathways in myotonic dystrophy type 1. Front Neurosci 19:1709678. https:\/\/doi.org\/10.3389\/fnins.2025.1709678","journal-title":"Front Neurosci"},{"key":"13888_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06206-0","author":"L Antoury","year":"2018","unstructured":"Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B et al (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-06206-0","journal-title":"Nat Commun"},{"key":"13888_CR183","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s10072-020-04409-2","volume":"41","author":"V Pegoraro","year":"2020","unstructured":"Pegoraro V, Cudia P, Baba A, Angelini C (2020) MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy. Neurol Sci 41:2953\u20132960. https:\/\/doi.org\/10.1007\/s10072-020-04409-2","journal-title":"Neurol Sci"},{"key":"13888_CR184","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4103\/neuroindia.ni_237_16","volume":"65","author":"KK Ambrose","year":"2017","unstructured":"Ambrose KK, Ishak T, Lian L-H, Goh K-J, Wong K-T, Ahmad-Annuar A et al (2017) Deregulation of microRNAs in blood and skeletal muscles of myotonic dystrophy type 1 patients. Neurol India 65:512. https:\/\/doi.org\/10.4103\/neuroindia.ni_237_16","journal-title":"Neurol India"},{"key":"13888_CR185","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150501","volume":"11","author":"JM Fernandez-Costa","year":"2016","unstructured":"Fernandez-Costa JM, Llamusi B, Bargiela A, Zulaica M, Alvarez-Abril MC, Perez-Alonso M et al (2016) Six serum miRNAs fail to validate as myotonic dystrophy type 1 biomarkers. PLoS ONE 11:e0150501. https:\/\/doi.org\/10.1371\/journal.pone.0150501","journal-title":"PLoS ONE"},{"key":"13888_CR186","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper GS, Bynum MLK, Somers EC (2009) Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33:197\u2013207. https:\/\/doi.org\/10.1016\/j.jaut.2009.09.008","journal-title":"J Autoimmun"},{"key":"13888_CR187","doi-asserted-by":"publisher","first-page":"e70293","DOI":"10.1111\/ene.70293","volume":"32","author":"A Pegat","year":"2025","unstructured":"Pegat A, Svahn J, Gerfaud\u2010Valentin M, Durel C, Durupt S, Bernard E (2025) IIgG4-related disease associated with myotonic dystrophy type 2. Eur J Neurol 32:e70293\u2013e70293. https:\/\/doi.org\/10.1111\/ene.70293","journal-title":"Eur J Neurol"},{"key":"13888_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.932883","author":"S Peric","year":"2022","unstructured":"Peric S, Zlatar J, Nikolic L, Ivanovic V, Pesovic J, Petrovic Djordjevic I et al (2022) Autoimmune diseases in patients with myotonic dystrophy type 2. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.932883","journal-title":"Front Neurol"},{"key":"13888_CR189","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/jnnp.2008.156562","volume":"80","author":"AA Tieleman","year":"2009","unstructured":"Tieleman AA, den Broeder A, van de Logt A-E, van Engelen BGM (2009) Strong association between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg Psychiatry 80:1293\u20131295. https:\/\/doi.org\/10.1136\/jnnp.2008.156562","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13888_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45535-1","volume":"15","author":"S R\u00f6sing","year":"2024","unstructured":"R\u00f6sing S, Ullrich F, Meisterfeld S, Schmidt F, Mlitzko L, Croon M et al (2024) Chronic endoplasmic reticulum stress in myotonic dystrophy type 2 promotes autoimmunity via mitochondrial DNA release. Nat Commun 15:1534. https:\/\/doi.org\/10.1038\/s41467-024-45535-1","journal-title":"Nat Commun"},{"key":"13888_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1041437","author":"MJ Damen","year":"2022","unstructured":"Damen MJ, den Broeder AA, Voermans NC, Tieleman AA (2022) Commentary: autoimmune diseases in patients with myotonic dystrophy type 2. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.1041437","journal-title":"Front Neurol"},{"key":"13888_CR192","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1084\/jem.20181031","volume":"215","author":"Y Chen","year":"2018","unstructured":"Chen Y, Sharma S, Assis PA, Jiang Z, Elling R, Olive AJ et al (2018) CNBP controls IL-12 gene transcription and Th1 immunity. J Exp Med 215:3136\u20133150. https:\/\/doi.org\/10.1084\/jem.20181031","journal-title":"J Exp Med"},{"key":"13888_CR193","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1093\/nar\/gkx071","volume":"45","author":"E Lee","year":"2017","unstructured":"Lee E, Lee TA, Kim JH, Park A, Ra EA, Kang S et al (2017) CNBP acts as a key transcriptional regulator of sustained expression of interleukin-6. Nucleic Acids Res 45:3280\u20133296. https:\/\/doi.org\/10.1093\/nar\/gkx071","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13888-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:21:07Z","timestamp":1783495267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13888-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":193,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13888"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13888-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.S. has received research grants from the EU Horizon 2022 programs ComPaSS, PaLaDIn, and ENTRY-DM, PepGen DM research; received consulting fees from Alexion, Amicus, Astellas, Avidity, Denali, Dyne, Sanofi, and Johnson & Johnson; honoraria from Alexion, Argenx, Astellas, Dyne, Kedrion, and Sanofi; support for attending meetings and\/or travel from Astellas, Amicus, and Sanofi; has participated in advisory boards for Amicus, Astellas, Avidity, Dyne, and Encoded; and declares no stocks or shares. B.S. and F.K. received a Mytonia Dystrophy Foundation pilot grant for DM2 Biomarker exploration. M.L., D.H.M., and P.M. declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"395"}}